Correlation Between Morgan Stanley and BioMark Diagnostics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Morgan Stanley and BioMark Diagnostics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Morgan Stanley and BioMark Diagnostics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Morgan Stanley Direct and BioMark Diagnostics, you can compare the effects of market volatilities on Morgan Stanley and BioMark Diagnostics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Morgan Stanley with a short position of BioMark Diagnostics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Morgan Stanley and BioMark Diagnostics.

Diversification Opportunities for Morgan Stanley and BioMark Diagnostics

-0.68
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Morgan and BioMark is -0.68. Overlapping area represents the amount of risk that can be diversified away by holding Morgan Stanley Direct and BioMark Diagnostics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioMark Diagnostics and Morgan Stanley is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Morgan Stanley Direct are associated (or correlated) with BioMark Diagnostics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioMark Diagnostics has no effect on the direction of Morgan Stanley i.e., Morgan Stanley and BioMark Diagnostics go up and down completely randomly.

Pair Corralation between Morgan Stanley and BioMark Diagnostics

Given the investment horizon of 90 days Morgan Stanley is expected to generate 2.75 times less return on investment than BioMark Diagnostics. But when comparing it to its historical volatility, Morgan Stanley Direct is 3.59 times less risky than BioMark Diagnostics. It trades about 0.04 of its potential returns per unit of risk. BioMark Diagnostics is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  14.00  in BioMark Diagnostics on September 14, 2024 and sell it today you would earn a total of  1.00  from holding BioMark Diagnostics or generate 7.14% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy45.36%
ValuesDaily Returns

Morgan Stanley Direct  vs.  BioMark Diagnostics

 Performance 
       Timeline  
Morgan Stanley Direct 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Morgan Stanley Direct are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite quite weak fundamental indicators, Morgan Stanley may actually be approaching a critical reversion point that can send shares even higher in January 2025.
BioMark Diagnostics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days BioMark Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's fundamental indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Morgan Stanley and BioMark Diagnostics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Morgan Stanley and BioMark Diagnostics

The main advantage of trading using opposite Morgan Stanley and BioMark Diagnostics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Morgan Stanley position performs unexpectedly, BioMark Diagnostics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioMark Diagnostics will offset losses from the drop in BioMark Diagnostics' long position.
The idea behind Morgan Stanley Direct and BioMark Diagnostics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Other Complementary Tools

ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
FinTech Suite
Use AI to screen and filter profitable investment opportunities